• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.机械线索通过甲羟戊酸-RhoA 轴控制突变型 p53 的稳定性。
Nat Cell Biol. 2018 Jan;20(1):28-35. doi: 10.1038/s41556-017-0009-8. Epub 2017 Dec 18.
2
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.SAHA 通过抑制 HDAC6-Hsp90 伴侣轴使突变型 p53 失稳,从而对突变型 p53 癌症细胞表现出优先的细胞毒性。
Cell Death Differ. 2011 Dec;18(12):1904-13. doi: 10.1038/cdd.2011.71. Epub 2011 Jun 3.
3
The stiff RhoAd from mevalonate to mutant p53.从甲羟戊酸到突变型p53的僵硬RhoAd。 (注:“RhoAd”可能是特定专业术语,具体准确含义需结合更多背景信息确定,这里按字面翻译)
Cell Death Differ. 2018 Mar;25(4):645-647. doi: 10.1038/s41418-018-0091-x. Epub 2018 Mar 6.
4
CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.CPUY201112是一种新型合成小分子化合物,也是热休克蛋白Hsp90的抑制剂,可诱导MCF-7细胞中p53介导的细胞凋亡。
Sci Rep. 2016 Jan 8;6:19004. doi: 10.1038/srep19004.
5
S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.S100A2是一种由BRCA1/p63共同调控的肿瘤抑制基因,在调节突变型p53稳定性方面发挥作用。
Cell Death Dis. 2014 Feb 20;5(2):e1070. doi: 10.1038/cddis.2014.31.
6
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.USP10-HDAC6 轴赋予缺乏野生型 p53 的非小细胞肺癌对顺铂的耐药性。
Cell Death Dis. 2020 May 7;11(5):328. doi: 10.1038/s41419-020-2519-8.
7
Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.人类乳腺癌中突变型p53的积累并非内在特性,也不依赖于结构或功能破坏,而是受外源性应激和受体状态调控。
J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.
8
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.通过p53-Hsp40调控轴将突变型p53小分子重激活为野生型样p53
Chem Biol. 2015 Sep 17;22(9):1206-16. doi: 10.1016/j.chembiol.2015.07.016. Epub 2015 Aug 27.
9
p53 and cancer stem cells: the mevalonate connexion.p53 与癌症干细胞:甲羟戊酸通路的关联。
Cell Cycle. 2012 Jul 15;11(14):2583-4. doi: 10.4161/cc.21092.
10
The interplay between mutant p53 and the mevalonate pathway.突变型 p53 与甲羟戊酸途径的相互作用。
Cell Death Differ. 2018 Mar;25(3):460-470. doi: 10.1038/s41418-017-0026-y. Epub 2017 Dec 13.

引用本文的文献

1
Substrate stiffness regulates triple-negative breast cancer signaling through CXCR4 receptor dynamics.底物硬度通过CXCR4受体动力学调节三阴性乳腺癌信号传导。
Sci Rep. 2025 Aug 13;15(1):29621. doi: 10.1038/s41598-025-14495-x.
2
Mechanical regulation of extracellular vesicle activity during tumour progression.肿瘤进展过程中细胞外囊泡活性的机械调节
Nat Biomed Eng. 2025 Aug 6. doi: 10.1038/s41551-025-01446-0.
3
Efficacy analysis of targeted P53 therapy in solid tumors.实体瘤中靶向P53治疗的疗效分析
Med Oncol. 2025 Jul 22;42(8):360. doi: 10.1007/s12032-025-02930-y.
4
Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.靶向突变型p53的药物发现及p53突变型癌症的纳米治疗策略进展
Biomolecules. 2025 May 26;15(6):763. doi: 10.3390/biom15060763.
5
β-adrenergic signaling modulates breast cancer cell mechanical behaviors through a RhoA-ROCK-myosin II axis.β-肾上腺素能信号通过RhoA-ROCK-肌球蛋白II轴调节乳腺癌细胞的力学行为。
iScience. 2025 May 15;28(6):112676. doi: 10.1016/j.isci.2025.112676. eCollection 2025 Jun 20.
6
Proteomic landscape of decellularized breast carcinomas identifies C-type lectin domain family 3 member A as a driver of cancer aggressiveness.脱细胞乳腺癌的蛋白质组学图谱确定C型凝集素结构域家族3成员A为癌症侵袭性的驱动因素。
NPJ Breast Cancer. 2025 Jun 6;11(1):51. doi: 10.1038/s41523-025-00769-0.
7
Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53.低剂量他汀类药物通过抑制突变型p53恢复乳腺癌细胞的固有免疫反应。
Front Pharmacol. 2025 May 2;16:1492305. doi: 10.3389/fphar.2025.1492305. eCollection 2025.
8
Primary cilia prevent activation of the cGAS-STING pathway during mouse decidualization.在小鼠蜕膜化过程中,初级纤毛可防止cGAS-STING通路的激活。
Commun Biol. 2025 Apr 14;8(1):607. doi: 10.1038/s42003-025-08030-x.
9
Glutathione reductase underlies the stability of mutant p53 by antagonizing protein glutathionylation.谷胱甘肽还原酶通过拮抗蛋白质谷胱甘肽化作用维持突变型p53的稳定性。
Redox Biol. 2025 Apr;81:103522. doi: 10.1016/j.redox.2025.103522. Epub 2025 Jan 30.
10
Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.脂肪生成酶FASN通过棕榈酰化促进突变型p53的积累和功能获得。
Nat Commun. 2025 Feb 19;16(1):1762. doi: 10.1038/s41467-025-57099-9.

本文引用的文献

1
Glucocorticoid receptor signalling activates YAP in breast cancer.糖皮质激素受体信号激活乳腺癌中的 YAP。
Nat Commun. 2017 Jan 19;8:14073. doi: 10.1038/ncomms14073.
2
Targeting mutant p53 in cancer: a long road to precision therapy.靶向癌症中的突变型 p53:通往精准治疗的漫长道路。
FEBS J. 2017 Mar;284(6):837-850. doi: 10.1111/febs.13948. Epub 2016 Nov 20.
3
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.DNAJA1通过甲羟戊酸途径控制错误折叠的突变型p53的命运。
Nat Cell Biol. 2016 Nov;18(11):1233-1243. doi: 10.1038/ncb3427. Epub 2016 Oct 24.
4
The interplay between cell signalling and the mevalonate pathway in cancer.细胞信号转导与癌症中的甲羟戊酸途径的相互作用。
Nat Rev Cancer. 2016 Nov;16(11):718-731. doi: 10.1038/nrc.2016.76. Epub 2016 Aug 26.
5
YAP/TAZ at the Roots of Cancer.YAP/TAZ与癌症根源
Cancer Cell. 2016 Jun 13;29(6):783-803. doi: 10.1016/j.ccell.2016.05.005.
6
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.YAP/TAZ/TEAD与增强子处的AP-1之间的全基因组关联驱动致癌生长。
Nat Cell Biol. 2015 Sep;17(9):1218-27. doi: 10.1038/ncb3216. Epub 2015 Aug 10.
7
Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.香叶基香叶基化信号可激活 Hippo 通路,促进乳腺癌细胞增殖和迁移。
Oncogene. 2015 Jun 11;34(24):3095-106. doi: 10.1038/onc.2014.251. Epub 2014 Aug 11.
8
TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.乳腺癌中 TP53 突变谱具有亚型特异性,并具有明显的预后相关性。
Clin Cancer Res. 2014 Jul 1;20(13):3569-80. doi: 10.1158/1078-0432.CCR-13-2943. Epub 2014 May 6.
9
Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.人类乳腺癌中突变型p53的积累并非内在特性,也不依赖于结构或功能破坏,而是受外源性应激和受体状态调控。
J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.
10
Metabolic control of YAP and TAZ by the mevalonate pathway.甲羟戊酸途径对 YAP 和 TAZ 的代谢调控。
Nat Cell Biol. 2014 Apr;16(4):357-66. doi: 10.1038/ncb2936. Epub 2014 Mar 23.

机械线索通过甲羟戊酸-RhoA 轴控制突变型 p53 的稳定性。

Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.

机构信息

Laboratorio Nazionale CIB, Area Science Park Padriciano, Trieste, Italy.

Laboratory of Metabolic Signaling, Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

出版信息

Nat Cell Biol. 2018 Jan;20(1):28-35. doi: 10.1038/s41556-017-0009-8. Epub 2017 Dec 18.

DOI:10.1038/s41556-017-0009-8
PMID:29255172
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6179142/
Abstract

Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function) . Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it does not represent an intrinsic property of p53 mutants, but rather requires secondary events . Moreover, mutant p53 protein levels are often heterogeneous even within the same tumour, raising questions on the mechanisms that control local mutant p53 accumulation in some tumour cells but not in their neighbours . By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment. Our results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues.

摘要

肿瘤相关的 p53 错义突变体作为驱动癌基因影响癌症进展、转移潜能和耐药性(获得功能)。突变 p53 蛋白的稳定是获得功能表现的前提条件;然而,它并不是 p53 突变体的固有特性,而是需要次级事件。此外,突变 p53 蛋白水平在同一肿瘤内甚至常常是异质的,这引发了关于控制局部突变 p53 在某些肿瘤细胞中积累而不在其相邻细胞中积累的机制的问题。通过研究诱导突变 p53 免受泛素介导的蛋白水解保护的细胞途径,我们发现,HDAC6/Hsp90 依赖性突变 p53 积累是由甲羟戊酸途径下游的 RhoA 异戊烯基化以及 RhoA 和肌动蛋白依赖性机械输入(如细胞外环境的硬度)转导所维持的。我们的结果为依赖代谢和机械线索的突变 p53 调节提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/dcd910f0343a/emss-79958-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/895a34fdc71a/emss-79958-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/3dd6ec75fd43/emss-79958-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/9625480ad4c2/emss-79958-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/1a54cc99de2a/emss-79958-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/dcd910f0343a/emss-79958-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/895a34fdc71a/emss-79958-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/3dd6ec75fd43/emss-79958-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/9625480ad4c2/emss-79958-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/1a54cc99de2a/emss-79958-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c26a/6179142/dcd910f0343a/emss-79958-f005.jpg